Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 14, 2021

View Archived Issues

Overcoming EGFR-targeted TKI lung cancer resistance

Sulfopin, a new selective Pin1 inhibitor with in vivo anticancer activity in Myc-driven tumors

Engineered microbial therapy for local metabolic modulation of the tumor microenvironment

AMPK is a therapeutic target in PDAC

BDNF and NSE as biomarkers in alcohol use disorder and mood disorder comorbidity

New EGFR inhibitors identified at PharmaBlock Sciences

Heptares Therapeutics describes new GLP-1 and GLP-2 receptor agonists

LG Chem discovers GLP-1 receptor agonists

Beijing Jacobio Pharmaceuticals patents KRAS mutant protein inhibitors

New adenosine receptor antagonists synthesized at Exelixis

Suicide attempters with schizophrenia show increased serum S-100B protein levels

CD38 as therapeutic target for protection against doxorubicin-induced cardiotoxicity

Ikena Oncology targets TEAD transcription in cancer with IK-930

BNIP3L is a molecular target in mitophagy defects and mitochondrial dysfunction

SparingVision and Intellia Therapeutics establish strategic collaboration for ocular diseases

Titan Pharmaceuticals and MUSC enter research agreement on kappa-opioid receptor agonists

Immusoft and Takeda to jointly develop cell therapies for neurometabolic disorders

Preclinical studies show potential of melanocortin agonists PL-8331 and PL-9654 for ocular diseases

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 11, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...